Titan Pharmaceuticals Historical PE Ratio image   This TTNP PE ratio history page last updated 5/30/2022
Titan Pharmaceuticals Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q1 2022
5/16/2022
0.50-0.24-0.96NA
Q4 2021
3/25/2022
1.01-0.26-1.04NA
Q3 2021
11/15/2021
1.62-0.19-0.76NA
Q2 2021
8/16/2021
2.14-0.17-0.68NA
Q1 2021
5/17/2021
2.43-0.28-1.12NA
Q4 2020
3/31/2021
2.98-0.81-3.24NA
Q3 2020
11/16/2020
3.60-1.50-6.00NA
Q2 2020
8/14/2020
8.40-1.50-6.00NA
Q1 2020
5/15/2020
8.40-2.10-8.40NA
Q4 2019
3/30/2020
8.10-2.40-9.60NA
Q3 2019
11/14/2019
5.70-5.40-21.60NA
Q2 2019
8/14/2019
21.00-11.40-45.60NA
Q1 2019
5/15/2019
51.30-10.20-40.80NA
Q4 2018
4/1/2019
55.20-18.60-74.40NA
Q3 2018
11/14/2018
84.60-19.80-79.20NA
Q2 2018
8/14/2018
162.00-7.20-28.80NA
Q1 2018
5/15/2018
145.80-21.60-86.40NA
Q4 2017
4/2/2018
180.00-30.60-122.40NA
Q3 2017
11/9/2017
284.40-36.00-144.00NA
Q2 2017
8/9/2017
279.00-30.60-122.40NA
Q1 2017
5/10/2017
441.00-28.80-115.20NA
Q4 2016
3/16/2017
684.00-27.00-108.00NA
Q3 2016
11/9/2016
810.00-21.60-86.40NA
Q2 2016
8/9/2016
923.4099.00396.002.3
Q1 2016
5/10/2016
997.20-16.20-64.80NA
Q4 2015
3/15/2016
666.00-19.80-79.20NA
Titan Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q1 2022
5/16/2022
0.50-0.24-0.69NA
Q4 2021
3/25/2022
1.01-0.26-0.62NA
Q3 2021
11/15/2021
1.62-0.19-0.64NA
Q2 2021
8/16/2021
2.14-0.17-1.26NA
Q1 2021
5/17/2021
2.43-0.28-4.09NA
Q4 2020
3/31/2021
2.98-0.81-5.91NA
Q3 2020
11/16/2020
3.60-1.50-7.50NA
Q2 2020
8/14/2020
8.40-1.50-11.40NA
Q1 2020
5/15/2020
8.40-2.10-21.30NA
Q4 2019
3/30/2020
8.10-2.40-29.40NA
Q3 2019
11/14/2019
5.70-5.40-45.60NA
Q2 2019
8/14/2019
21.00-11.40-60.00NA
Q1 2019
5/15/2019
51.30-10.20-55.80NA
Q4 2018
4/1/2019
55.20-18.60-67.20NA
Q3 2018
11/14/2018
84.60-19.80-79.20NA
Q2 2018
8/14/2018
162.00-7.20-95.40NA
Q1 2018
5/15/2018
145.80-21.60-118.80NA
Q4 2017
4/2/2018
180.00-30.60-126.00NA
Q3 2017
11/9/2017
284.40-36.00-122.40NA
Q2 2017
8/9/2017
279.00-30.60-108.00NA
Q1 2017
5/10/2017
441.00-28.8021.6020.4
Q4 2016
3/16/2017
684.00-27.0034.2020.0
Q3 2016
11/9/2016
810.00-21.6041.4019.6
Q2 2016
8/9/2016
923.4099.00NANA
Q1 2016
5/10/2016
997.20-16.20NANA
Q4 2015
3/15/2016
666.00-19.80NANA
Quotes delayed 20 minutes

Email EnvelopeFree TTNP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Titan Pharmaceuticals (TTNP) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

TTOO PE Ratio History
TVTX PE Ratio History
TVTY PE Ratio History
TWST PE Ratio History
TXG PE Ratio History
TXMD PE Ratio History
TYME PE Ratio History
UBX PE Ratio History
UHS PE Ratio History
UNCY PE Ratio History
How should the TTNP historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Titan Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this TTNP Historical PE Ratio page.

What is the average historical PE for TTNP based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The TTNP historical PE ratio using the annualized quarterly earnings method works out to 2.3.

What is the average historical PE for TTNP based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The TTNP historical PE ratio using the TTM earnings method works out to 20.0.

On this page we presented the Titan Pharmaceuticals Historical PE Ratio information for Titan Pharmaceuticals' stock. The average TTNP historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 2.3. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average TTNP historical PE based on this TTM earnings result method is 20.0. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this TTNP historical PE result, against the recent PE: when this page was posted on 5/27/2022, the most recent closing price for TTNP had been 0.42, and the most recent quarterly earnings result, annualized, was 396. Meanwhile, the most recent TTM earnings summed to 21.6. From these numbers, we calculate the recent TTNP PE on 5/27/2022 based on annualized quarterly EPS was 0.0. Based on TTNP's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the historical average PE across our data set for Titan Pharmaceuticals. Looking at the recent TTNP PE on 5/27/2022 based on TTM EPS, we calculate the ratio at 0.0. Based on TTNP's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the average PE across our Titan Pharmaceuticals data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on TTNP or any other given stock, valuation analysis for TTNP can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Titan Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for TTNP. Thanks for visiting, and the next time you need to research TTNP Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Institutional Holders of ARA, ROAD Stock Predictions, Funds Holding HIFR.

 

Titan Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.